Open AccessDo drugs that target mTOR generate CCN2‐mediated fibrogenic side effects?
Author(s) -
Leask Andrew
Publication year - 2019
Publication title -
journal of cell communication and signaling
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 44
eISSN - 1873-961X
pISSN - 1873-9601
DOI - 10.1007/s12079-019-00520-y
Subject(s) - pi3k/akt/mtor pathway , discovery and development of mtor inhibitors , medicine , sirolimus , fibrosis , cancer research , lung , pharmacology , bioinformatics , signal transduction , biology , microbiology and biotechnology
mTOR, the target of rapamycin, has been promoted as a potential target for cancers, transplantations and even lung fibrosis. However, paradoxically, targeting mTOR has been reported to result in profibrotic side effects. Some recent publications highlight why this might be.